{"analyses":[{"ciPctValue":"95","groupDescription":"The study required an estimated sample size of 720 patients (360 per arm) in order to detect a 25% reduction in the hazard ratio for death in the cabazitaxel group relative to the mitoxantrone group with 90% power. The final analysis was planned for when 511 deaths had occurred.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"A 2-sided significance level of 0.0452 was used for the final analysis based on an interim analysis performed after 307 events with an adjusted significance level of 0.016 based on the O'Brien-Fleming type 1 error spending function.","statisticalComment":"Analysis was performed by using a log-rank comparisons stratified according to disease measurability and ECOG performance status (0-1 versus 2)","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.6","upperLimit":"13.7","value":"12.7"},{"groupId":"OG001","lowerLimit":"14.1","upperLimit":"16.3","value":"15.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"378"}],"units":"Participants"}],"description":"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.\n\nIn the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first.","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the intention To Treat (ITT) population. The ITT population is composed of all randomized patients (i.e. patients assigned to a treatment group by the randomization, regardless of whether patients received any study drug or received a different study drug from which they were randomized).","reportingStatus":"POSTED","timeFrame":"From the date of randomization up to 104 weeks (study cut-off)","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}